Bionano Genomics, Inc.
Description
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
About
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Employees
344
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Instruments & Supplies
MIC code
XNCM
Address
9540 Towne Centre Drive, San Diego, CA 92121, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Mar 4, 2025 | — | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 2 |
| Average estimate | — | -8.40 | — | -28.80 |
| Low estimate | — | -8.40 | — | -30.60 |
| High estimate | — | -8.40 | — | -27.00 |
| Last year EPS | — | -30.48 | — | -60.60 |
[stock_revenue_estimate]
Growth estimates
Current qtr
85.420%
Next qtr. (Mar 2025)
72.440%
Current year
85.170%
Next year (Dec 2025)
52.480%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 36.12M | 27.80M | 17.98M | 8.50M | 10.13M |
| Cost of revenue | 26.55M | 21.86M | 14.11M | 5.73M | 6.77M |
| Gross profit | 9.57M | 5.95M | 3.87M | 2.77M | 3.36M |
| Operating expense | |||||
| Research & development | 54.03M | 49.05M | 22.49M | 10.26M | 9.08M |
| Selling general and admin | 93.50M | 88.60M | 58.49M | 31.07M | 20.16M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -137.97M | -131.70M | -77.10M | -38.55M | -25.87M |
| Non operating interest income | |||||
| Income | 3.31M | 1.51M | 236,000 | — | — |
| Expense | 5.12M | 298,000 | 927,000 | 2.52M | 2.29M |
| Other income expense | -92.66M | -223,000 | -360,000 | -7,000 | -1.63M |
| Pretax income | -232.43M | -130.71M | -78.15M | -41.08M | -29.79M |
| Tax provision | 62,000 | 1.88M | -5.72M | 29,000 | 21,048 |
| Net income | -232.49M | -132.60M | -72.44M | -41.11M | -29.82M |
| Basic EPS | -6.81 | -4.46 | -2.50 | -2.16 | -8.70 |
| Diluted EPS | -6.81 | -4.46 | -2.50 | -2.16 | -8.70 |
| Basic average shares | 34.15M | 29.72M | 28.96M | 19.00M | 3.43M |
| Diluted average shares | 34.15M | 29.72M | 28.96M | 19.00M | 3.43M |
| EBITDA | -136.12M | -120.57M | -73.55M | -37.08M | -25.05M |
| Net income from continuing op. | -232.49M | -132.60M | -72.44M | -41.11M | -29.82M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 214.40M | 307.50M | 377.10M | 60.45M | 30.21M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 17.95M | 5.09M | 24.57M | 38.45M | 17.31M |
| Other short term investments | 83.94M | 108.10M | 226.04M | — | — |
| Accounts receivable | 9.32M | 7.02M | 4.93M | 2.78M | 6.33M |
| Other receivables | — | — | — | — | — |
| Inventory | 22.89M | 29.76M | 12.39M | 3.32M | 3.44M |
| Prepaid assets | 4.70M | 4.44M | 2.72M | 1.79M | 712,284 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 976,000 | 2.41M | 1.38M | 462,000 | 457,062 |
| Non current assets | |||||
| Properties | 44.83M | 36.41M | 26.51M | 9.99M | 5.87M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.98M | 1.62M | 819,000 | 492,000 | 476,402 |
| Construction in progress | — | — | — | — | — |
| Leases | 3.75M | 4.00M | 2.67M | 1.89M | 1.88M |
| Accumulated depreciation | -19.08M | -13.08M | -9.07M | -7.46M | -6.27M |
| Goodwill | 33.97M | 195.72M | 139.16M | 15.82M | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 33.97M | 41.14M | 26.84M | 1.48M | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 7.83M | 2.81M | 749,000 | 103,000 | — |
| Total liabilities | 118.25M | 58.10M | 39.98M | 25.37M | 26.59M |
| Current liabilities | |||||
| Accounts payable | 10.38M | 12.53M | 10.77M | 2.93M | 2.70M |
| Accrued expenses | 1.94M | 2.71M | 2.59M | 1.67M | 885,663 |
| Short term debt | 72.24M | 2.55M | 1.77M | — | 20.08M |
| Deferred revenue | 800,000 | 888,000 | 1.51M | 416,000 | 623,774 |
| Tax payable | 1.10M | 825,000 | 677,000 | 562,000 | 268,129 |
| Pensions | 5.03M | 7.00M | 4.53M | 3.25M | 1.81M |
| Other current liabilities | 8.53M | 9.38M | 175,000 | 113,000 | — |
| Non current liabilities | |||||
| Long term debt | 7.18M | 9.12M | 8.93M | 16.33M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 10.89M | 12.97M | 9.07M | — | 44,479 |
| Shareholders equity | |||||
| Common stock | 5,000 | 3,000 | 29,000 | 19,000 | 3,427 |
| Retained earnings | -581.21M | -348.72M | -216.12M | -143.68M | -102.58M |
| Other shareholders equity | 23,000 | -1.12M | -539,000 | — | — |
| Total shareholders equity | 96.16M | 249.40M | 337.12M | 35.08M | 3.61M |
| Additional paid in capital | 677.34M | 599.23M | 553.75M | 178.75M | 106.19M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -232.49M | -132.60M | -72.44M | -41.11M | -29.82M | -18.50M | -23.37M | -18.85M |
| Depreciation | 13.91M | 9.84M | 3.37M | 1.48M | 1.13M | 1.32M | 1.50M | 1.12M |
| Deferred Taxes | — | 1.76M | -5.78M | — | — | — | — | — |
| Stock-Based Compensation | 15.18M | 22.42M | 9.72M | 1.55M | 1.35M | 1.19M | 382,830 | 130,643 |
| Other Non-Cash Items | -2.98M | 794,000 | 1.48M | 1.26M | 883,269 | 865,938 | 96,576 | 73,902 |
| Accounts Receivable | -2.30M | -2.25M | -493,000 | 2.09M | -2.37M | -900,119 | -1.77M | -856,098 |
| Accounts Payable | -2.00M | 1.95M | 6.78M | -1.81M | 1.36M | -954,377 | 1.54M | -608,653 |
| Other Assets & Liabilities | -9.17M | -24.81M | -16.58M | -4.20M | -3.64M | -418,984 | -336,046 | -726,138 |
| Operating Cash Flow | -219.85M | -122.89M | -73.93M | -40.73M | -31.11M | -17.39M | -21.94M | -19.72M |
| Investing Activities | ||||||||
| Capital Expenditures | -1.69M | -3.17M | -1.46M | — | -61,056 | -331,716 | -1.02M | -1.35M |
| Net Intangibles | — | -102,000 | — | — | — | — | — | — |
| Net Acquisitions | 96,000 | -31.34M | -49.09M | -2.45M | — | — | — | — |
| Purchase of Investments | -111.26M | -84.20M | -313.39M | — | — | — | — | — |
| Sale of Investments | 137.02M | 200.89M | 86.48M | — | — | — | — | — |
| Investing Cash Flow | 24.16M | 82.87M | -278.06M | -2.45M | -61,056 | -331,716 | -1.02M | -1.35M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | — | — | — | 1.77M | 19.13M | 23.83M | — | 6.89M |
| Long-Term Debt Payments | -9.05M | -36,000 | -15.01M | -7.26M | -14.43M | -7.45M | — | -5.00M |
| Other Financing Charges | -14.97M | -578,000 | -1.70M | -2.00M | — | — | — | — |
| Financing Cash Flow | 33.69M | 22.51M | 326.00M | 30.95M | 25.76M | 35.77M | 17.59M | 25.43M |
| Other Cash Details | ||||||||
| End Cash Position | 18.35M | 5.49M | 24.57M | 38.45M | 17.31M | 16.52M | 1.02M | 5.25M |
| Income Tax Paid | — | — | — | — | — | — | — | — |
| Interest Paid | 1.65M | 298,000 | 1.91M | 1.25M | 1.28M | 700,353 | 534,858 | 446,525 |
| Free Cash Flow | -126.87M | -128.12M | -73.39M | -38.31M | -29.59M | -20.28M | -21.84M | -24.85M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 22,741 | 122,346 | 0.02% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 8,422 | 45,310 | 0.01% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 8,147 | 43,830 | 0.01% |
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 173 | 930 | 0.00% |
| Price (T.Rowe) U.S. Equities Trust | Sep 30, 2024 | 1,173 | 6,310 | 0.00% |
| Fidelity Total Market Index Fund | Nov 30, 2024 | 2,771 | 14,907 | 0.00% |
| Fidelity Series Total Market Index Fund | Nov 30, 2024 | 1,939 | 10,431 | 0.00% |
Article
Bionano Announces Effective Date of Reverse Stock Split
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-60. The effective time of the reverse stock split will be 5 p.m.
Jan 22, 2025
Article
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”).
Jan 6, 2025
Article
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.252 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”) for a period of five years thereafter.
Jan 3, 2025
